RiverVest


RiverVest Venture Partners is a venture capital firm founded in 2000 that builds and funds life‑science companies, focused on biopharmaceuticals and medical devices. The firm leads financings, founds companies, provides board and operational support, and leverages scientific, clinical, regulatory and reimbursement expertise to advance products that address unmet medical needs while delivering returns to investors.

RiverVest

St Louis, Missouri, United States, North America


Services

Direct and lead financings; company founding

Leads financings, founds companies, structures financing terms and builds investor syndicates to position companies for growth and exit events.

Strategic guidance and operating support

Collaborates with management teams on company strategy, operating plans, hiring and board composition to accelerate product development and commercialization.

Due diligence and scientific evaluation

Provides in‑house diligence and access to a network of scientific, regulatory, clinical and reimbursement experts for investment evaluation and portfolio support.

Follow‑on funding and syndicate support

Provides or helps secure follow‑on financing and connects companies with co‑investors and later‑stage capital sources.

Network access and commercialization support

Provides geographic diversification, access to entrepreneurs, industry investors and commercialization partners, and introductions to scientific and clinical experts.


Portfolio

No‑implant approach addressing chronic heart failure; referenced in firm 'Portfolio Company Spotlight'.

#Medical Device

Portfolio company with recent leadership transition (press release referenced).

#Biopharma

Developing inhaled therapies for pulmonary fibrosis; multiple financing and clinical milestones referenced.

#Biopharma

Developing a biowearable platform for metabolic health; announced Series C and strategic collaborations.

#Medical Device

Developing monoclonal antibodies for hepatitis B and D; received FDA breakthrough and EMA designations and advanced clinical trials.

#Biopharma

Developing GLM101 for PMM2‑CDG; announced Series C financing and clinical progress.

#Biopharma

View All Portfolio Items

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.